首页> 外文OA文献 >Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement:Results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3)

【2h】

Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement:Results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3)

机译：ixekizumab与依那西普和安慰剂相比，对中重度斑块状银屑病和非脓疱性掌跖受累患者的疗效：三项3期试验（UNCOVER-1，UNCOVER-2和UNCOVER-3）的结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Menter, A; Warren, R. B.; Langley, R. G.; Merola, J. F.; Kerr, L. N.; Dennehy, E. B.; Shrom, D.; Amato, D.; Okubo, Yukari; Reich, K;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种 eng
中图分类

相似文献

外文文献
中文文献

1. Ixekizumab impact on health-related quality of life compared to etanercept and placebo: Results from UNCOVER-2, a phase 3 trial in patients with moderate-to-severe plaque psoriasis [J] . Reich Kristian, Toth Darryl, Nikai Enkeleida, The Journal of investigative dermatology. . 2015,第Suppla3期

机译：与依那西普和安慰剂相比，伊克珠单抗对健康相关生活质量的影响：UNCOVER-2的结果，UNCOVER-2是一项针对中度至重度斑块状牛皮癣患者的3期试验
2. Ixekizumab impact on itch severity compared to etanercept and placebo: Results from UNCOVER-2, a phase 3 trial in patients with moderate-to-severe plaque psoriasis [J] . Kimball Alexa Boer, Nikai Enkeleida, Zhu Baojin, The Journal of investigative dermatology. . 2015,第Suppla3期

机译：与依那西普和安慰剂相比，伊克珠单抗对瘙痒严重程度的影响：UNCOVER-2的结果，一项针对中度至重度斑块状牛皮癣的3期试验
3. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis and non‐pustular palmoplantar involvement: results from three phase 3 trials ( UNCOVER UNCOVER ‐1, UNCOVER UNCOVER ‐2 and UNCOVER UNCOVER ‐3) [J] . Menter A., Warren R.B., Langley R.G., Journal of the European Academy of Dermatology and Venereology: JEADV . 2017,第10期

机译：与中度至重度斑块牛皮癣和非脓疱型棕榈术患者患者的伊斯康康和安慰剂的疗效与非脓疱棕榈术中的疗效相比：三相3试验结果（揭露揭露-1，揭示揭露-2和揭露undover -3）的结果
4. Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3) [O] . Andrew Blauvelt, Kim A. Papp, Christopher E. M. Griffiths, -1

机译：校正至：在Etanercept非应答者中改用伊克珠单抗的疗效和安全性：中度至重度斑块状牛皮癣的两个III期随机临床试验的亚分析（UNCOVER-2和-3）
5. Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes [O] . L Puig, M Dossenbach, L Berggren, 2019

机译：绝对和相对牛皮癣区域和严重程度指数（PASI），用于比较Ixekizumab与中度至严重的斑块牛皮癣患者依赖伊沙康和安慰剂的疗效：对揭露-2和未发现的3个结果的综合分析

Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement:Results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3)

著录项

引文网络

相似文献

相关主题

期刊订阅